Methylated biomarker combination for detecting metastatic prostate cancer tumor load and application

The detection kit made by a combination of methylated biomarkers solves the false positive and false negative problems in prostate cancer tumor burden detection, achieves efficient and accurate detection, and supports personalized treatment strategies.

CN118910252AInactive Publication Date: 2024-11-08SUZHOU DANBEI MEDICAL TECHNOLOGY GROUP CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410683942.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-25
Filing Date
2024-05-30
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing prostate cancer tumor burden detection methods have false positive and false negative problems, and cannot effectively distinguish between high tumor burden and low tumor burden, making it difficult to achieve different treatment strategies.

Method used

Using a combination of methylated biomarkers, DNA methylated molecular markers are highly correlated with prostate cancer, and an detection kit is made to detect the tumor burden of metastatic prostate cancer and improve the sensitivity and specificity of the detection.

Benefits of technology

Through non-invasive detection, the detection accuracy and sensitivity of metastatic prostate cancer are significantly improved, the false positive and false negative rates are reduced, and the accurate distinction between high and low tumor burden is achieved, which is of clinical promotion value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910252A_ABST
    Figure CN118910252A_ABST
Patent Text Reader

Abstract

The invention discloses a methylated biomarker combination for detecting metastatic prostate cancer tumor load and application, the methylated biomarker combination is selected from 171 methylated biomarkers, the methylated biomarker combination is used for preparing a detection kit, and the detection kit is applied to tumor load diagnosis of prostate cancer. According to the present invention, the high correlation between the DNA methylation molecular marker and the prostate cancer is utilized, and the methylation biomarker is combined to prepare the detection kit, such that the detection kit can be used for the metastatic prostate cancer tumor load detection, and the metastatic prostate cancer tumor load detection can be achieved in the non-invasive manner; compared with an existing detection method, the method has the obvious progressive advantages of noninvasive diagnosis, convenience and rapidness, the practicability is greatly improved, and the method has great clinical popularization feasibility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomarker combination applications, and in particular to a methylation biomarker combination and application for detecting metastatic prostate cancer tumor load. Background Art

[0002] Prostate cancer is the second most common cancer and the fifth leading cause of cancer-related death in men. The incidence of prostate cancer in developed countries is 37.5 per 100,000 people, and in developing countries it is 11.3 per 100,000 people, while the mortality rate is 8.1 per 100,000 people in developed countries and 5.9 per 100,000 people in developing countries. However, according to the latest national cancer report released by the China Cancer Center, the incidence of prostate cancer in my country has increased significantly in recent years, ranking sixth among male tumors, especially in large cities in China such as Shanghai, where the incidence of prostate cancer is even higher, ranking fourth among male malignant tumors, surpassing liver cancer. Currently, about 10 million men have been diagnosed with prostate cancer. Prostate cancer causes more than 400,000 deaths worldwide each year, and by 2040, the mortality rate is expected to reach more than 800,000 per year.

[0003] The increasing number of patients not only imposes a great economic burden on society and families, but also brings more pain to patients and reduces their quality of life. The clinical staging of newly diagnosed prostate cancer patients in China is very different from that in Western developed countries. Taking the United States as an example, among newly diagnosed prostate cancer patients, clinically localized cases account for 76%, local lymph node metastasis cases account for 13%, and distant metastasis cases account for only 6% (the remaining 5% are cases of unknown stage). Data from a multicenter study in China show that only 1 / 3 of newly diagnosed prostate cancer patients have clinically localized prostate cancer, and most patients are already in the middle and late stages at the time of initial diagnosis, resulting in the overall prognosis of Chinese prostate cancer patients being far worse than that in Western developed countries. At present, the proportion of patients with high-risk or metastatic disease at the initial treatment in my country is about 50%, which is less than 70% in 2015, but is still far from the level of European and American countries.

[0004] The CHAARTED study defined high tumor burden as visceral metastasis, or ≥4 bone metastatic lesions, at least 1 of which was outside the spine or pelvis. Low tumor burden was defined as no visceral metastasis and ≤3 bone metastatic lesions. The number of metastatic lesions and tumor burden in patients with metastatic prostate cancer are related to treatment prognosis. For example, surgery-based primary lesion treatment is expected to improve the prognosis of patients with low tumor burden and has better safety, while surgical treatment of patients with high tumor burden has little benefit. The treatment strategies for patients with different tumor burdens vary, and the indications for different treatment options are also different. Therefore, for patients with metastatic prostate cancer, the guidelines recommend stratifying patients according to low tumor burden and high tumor burden, and clinical treatment also needs to be stratified.

[0005] cfDNA (circulating cell-free DNA) is a small fragment of DNA that is free in peripheral blood. It mainly originates from tumor-related necrosis or physiological apoptosis and contains genetic information such as somatic mutations and DNA methylation. Detection methods such as cfDNA, circulating tumor cells (CTCs) or exosomes in the blood are called liquid biopsy. Compared with traditional tissue biopsies, it has many advantages such as rapidity, low risk, low cost and low invasiveness. To date, many studies have confirmed that information on cancer-related DNA mutations or methylation modification variations can be detected from cfDNA of cancer patients. In 2017, Wyatt's team proved that all somatic mutations found in prostate cancer metastatic tissues also appeared in matching cfDNA samples. More and more clinical studies have shown that cfDNA can be used as a biomarker in the diagnosis and prognosis of prostate cancer patients.

[0006] Currently, the main methods for examining prostate cancer tumor burden are bone scanning (ECT) and targeted prostate-specific membrane antigen (PSMA) PET / CT. Prostate cancer usually first metastasizes to the bone. When diagnostic examinations are required, technetium-99 radionuclide bone scanning is still the standard method for evaluating bone metastases. Although bone scanning has high sensitivity, it lacks specificity. In fractures or injuries or local inflammation or degeneration, because of the osteogenesis process in bone repair, there will also be signal concentration, which can also cause false positive bone scans. Therefore, patients with positive or unclear bone scans usually need further examination. In recent years, the application of PSMA PET / CT imaging in the diagnosis and treatment of prostate cancer has gradually increased. PSMA PET / CT is more accurate and comprehensive than conventional imaging methods in detecting occult lymph node and bone metastases. Commonly used 68 Ga-labeled PSMA-type imaging agents are mainly excreted through the urinary system, and are prone to miss small metastatic lesions or local recurrent lesions around the bladder. At the same time, about 10% of patients have low expression of PSMA in tumor lesions, and PSMA PET imaging is negative. PSMA is not only highly expressed in prostate cancer cells, but also in the neovascular endothelial cell membranes of many solid tumors such as lung cancer, kidney cancer, colon cancer, thyroid cancer, brain tumors, etc., which can express PSMA to a certain extent, and PSMAPET / CT shows positive results. In addition, non-specific uptake of PSMA PET imaging agents can also be seen in a variety of benign lesions such as bronchiectasis with infection, sarcoidosis, Paget's disease, and ganglia. PSMA PET / CT is expensive, and false positives and false negatives plague the judgment of imaging results. Its detection efficiency needs more research to explore and confirm.

[0007] Authoritative guidelines at home and abroad stratify the treatment of prostate cancer according to high tumor load and low tumor load. The detection of prostate cancer not only needs to detect whether it has metastasized, but also needs to detect its tumor load. Previous test kits basically did not detect prostate tumor load, and imaging tests were limited by false negatives and false positives. Therefore, it is necessary to invent a combination of methylation biomarkers for detecting metastatic prostate and their application to solve the above problems. Summary of the invention

[0008] The purpose of the present invention is to provide a methylation biomarker combination and application for detecting the tumor burden of metastatic prostate cancer. By utilizing the high correlation between DNA methylation molecular markers and prostate cancer, a detection kit is prepared by combining methylation biomarkers, which can be used for the detection of metastatic prostate cancer. The detection of metastatic prostate cancer tumor burden can be achieved in a non-invasive manner, thereby improving the sensitivity, specificity and accuracy of the detection of metastatic prostate cancer, so as to solve the above-mentioned deficiencies in the technology.

[0009] In order to achieve the above object, the present invention provides the following technical solutions:

[0010] A methylation biomarker panel for detecting tumor burden in metastatic prostate cancer selected from the following global panel of methylation biomarkers:

[0011] chr1:1137001-1137301、chr1:145573620-145573920、chr1:155620501-155620801、chr1:184006347-184006405、chr1:205631898-205632198、chr1:230208001-230208301、chr1:29564367-29564667、chr1:58234801-58235101、chr1:87767701-87768001、chr1:91089001-91089301、chr1:147487202-147487501、chr1:147532802-147533101、chr1:181059009-181059309、chr1:181059309-181059609、chr1:94146733-94146927、chr10:133506601-133506901、chr10:2095501-2095801、chr10:482262-482562、chr10:77158920-77159220、chr10:91330501-91330801、chr10:17270986-17271286、chr10:73156539-73156552、chr10:79397203-79397502、chr11:2867401-2867701、chr11:45672001-45672301、chr11:64875601-64875901、chr11:836101-836401、chr11:86900101-86900401、chr11:17373393-17373693、chr12:125076301-125076601、chr12:125139301-125139601、chr12:133353801-133354101、chr12:87835801-87836101、chr12:104851940-104852240、chr12:49393272-49393353、chr14:90849279-90849579、chr14:91579987-91580287、chr15:102303001-102303301、chr15:39872388-39872688、chr15:102286047-102286347、chr15:45479869-45480127、<h2 style=";text-align:left;direction:ltr">chr15: 72667882-72668182、chr16: 1730317-1730617、chr16: 5337901-53 38201、chr16:83691601-83691901、chr17:80072101-80072401、chr17:316 19207-31619225, chr18: 150901-151201, chr18: 76273801-76274101, chr19: 16680412-16680712, chr19: 29613901-29614201, chr19: 38978952-389 79252, chr19: 38996401-38996701, chr19: 49703623-49703923, chr19: 49703923-49704223, chr19: 50944201-50944501, chr19: 51303278-51303578 、chr19: 39282525-39282825、chr2: 170552044-170552344、chr2: 1705523 44-170552375、chr2:177023775-177024075、chr2:20068960-20069094、ch r2:2275801-2276101、chr2:240033301-240033601、chr2:240033601-240 033901、chr2:47703601-47703901、chr2:88690201-88690501、chr2:99796 148-99796448, chr20: 29804820-29805120, chr20: 56247772-56248072, chr20: 4803590-4803717, chr21: 11169301-11169601, chr21: 27041008-270 41308, chr21: 45078301-45078601, chr21: 28219250-28219313, chr22: 39855601-39855901, chr22: 46969801-46970101, chr22: 51177001-51177301 chr22: 24199607-24199629, chr3: 145173301-145173601, chr3: 184243114-184243414, chr3: 193119901-193120201, chr3: 197113944-197114244<h2 style=";text-align:left;direction:ltr">chr3:79606801-79607101、chr3:93744201-93744501、chr3:98381701-9 8382001、chr3:50274237-50274536、chr4:1039501-1039801、chr4:15172 6801-151727101、chr4:44450164-44450464、chr4:9241061-9241361、chr 4:9245629-9245929、chr4:185937927-185937986、chr5:111409501-1114 09801, chr5: 149985301-149985601, chr5: 171576901-171577201, chr5: 175119901-175120201, chr5: 178398013-178398313, chr5: 178408306-178 408606、chr5:63373501-63373801、chr5:79331327-79331526、chr5:9495 6093-94956392、chr6:131404801-131405101、chr6:161273487-16127378 7、chr6: 105584593-105584757、chr6: 107810663-107810821、chr6: 1313 83975-131383979、chr6:26189401-26189431、chr7:144835801-14483610 1, chr7: 154592101-154592401, chr7: 155135101-155135401, chr7: 157485729-157486029, chr7: 20823318-20823618, chr7: 56230801-56231101, c hr7:56357341-56357641,chr7:7605460-7605760,chr7:7606060-7606112,chr7:7612688-7612988,chr7:7612988-7613288,chr7:7613288-76135 88, chr7: 134144180-134144289, chr7: 23513704-23514004, chr7: 23514004-23514120, chr8: 110882401-110882701, chr8: 126445404-126445704chr8: 131455029-131455329, chr8: 55002982-55003282, chr8: 65711134-6571 1434, chr8: 7830601-7830901, chr8: 86566135-86566435, chr8: 95182801-9518 3101, chr8: 99954843-99955143, chr8: 144853418-144853717, chr9: 130529101 -130529401, chr9: 137378101-137378401, chr9: 44868901-44869201, chr9: 973 17483-97317783, chr9: 102585769-102586068, chr9: 27529891-27530023, chr 9: 37036916-37037215, chr9: 93955005-93955305, chrX: 100672978-100673278 、chrX:114468337-114468637、chrX:115005001-115005301、chrX:32723401-32723701、chrY:13489201-13489501 and 35 other methylation markers derived from Chinese patent application No. 202211120273.0. 、

[0012] As a preferred embodiment of the present invention, the methylation biomarker combination is used to prepare a detection kit.

[0013] As a preferred embodiment of the present invention, the detection kit is used to detect prostate cancer tumor load.

[0014] The detection method of the methylation biomarker combination includes the above-mentioned methylation biomarker combination and the detection kit prepared therefrom, and the detection steps are as follows:

[0015] Step 1: extracting cfDNA from a blood sample to be tested; the blood sample is plasma, serum or blood;

[0016] Step 2: Treat the extracted cfDNA with bisulfite to obtain a converted cfDNA sample;

[0017] Step 3: Construct a methylated DNA library for the converted cfDNA samples;

[0018] Step 4: Construction of targeted hybrid capture methylation and library for prostate cancer;

[0019] Step 5: high-throughput sequencing to obtain probe-captured data. The sequencing can be performed by any sequencing method, including but not limited to the dideoxy chain termination method, preferably the high-throughput sequencing method includes but is not limited to the second-generation sequencing technology or the single-molecule sequencing technology;

[0020] Step 6: Methylation data analysis: confirm the final metastatic prostate cancer score and metastatic tumor burden score based on the methylation markers and algorithm model.

[0021] As a preferred embodiment of the present invention, during the methylation data analysis in step 6, conventional bioinformatics analysis and processing is performed on the raw data from the sequencer.

[0022] Methods for detecting DNA methylation are well known in the art, and the detection method used is to use pyrophosphate sequencing, bisulfite conversion sequencing, methylation chip method, fluorescence quantitative qPCR method, digital PCR method, second generation sequencing method, third generation sequencing method, whole genome and various combinations thereof methylation sequencing method, DNA enrichment detection method, simplified bisulfite sequencing technology, methylation sensitive restriction enzyme analysis method, HPLC method, MassArray, methylation specific PCR, or reagents used in combination thereof. In one or more embodiments, detection includes detecting any strand at a gene or site.

[0023] In the above technical solution, the technical effects and advantages provided by the present invention are:

[0024] By utilizing the high correlation between DNA methylation molecular markers and prostate cancer, and by combining methylation biomarkers to make a detection kit, it can be used to detect the tumor burden of metastatic prostate cancer. The detection of metastatic prostate cancer tumor burden can be achieved in a non-invasive manner, which improves the sensitivity, specificity and accuracy of the detection of metastatic prostate cancer. Compared with existing detection methods, it has the obvious advantages of non-invasive diagnosis and convenience and speed, greatly improves its practicality, and has great feasibility for clinical promotion. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present invention. For ordinary technicians in this field, other drawings can also be obtained based on these drawings.

[0026] Figure 1 Schematic diagram of 171-site screening, model algorithm construction and algorithm use flow of the algorithm model for the metastatic prostate cancer score and prostate cancer metastasis load score in Example 1 of the present invention.

[0027] Figure 2 This is a ROC diagram of the application of cfDNA methylation in the diagnosis of metastatic prostate cancer in Example 2 of the present invention;

[0028] Figure 3 is a prediction score graph of metastatic prostate cancer in Example 2 of the present invention;

[0029] Figure 4 The ROC curve generated for the comparison between high tumor load and low tumor load in Example 3 of the present invention; DETAILED DESCRIPTION

[0030] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described in detail below with reference to the accompanying drawings.

[0031] The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions, such as the conditions described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). The materials, reagents, instruments, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0032] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0033] In one aspect, disclosed herein is a method for disease diagnosis based on sequencing data (eg, nucleic acid) from a blood sample. cfDNA is used as a primary example throughout the application, but it should not limit the scope of the invention in any way.

[0034] The present invention provides a methylation biomarker combination for detecting metastatic prostate cancer, selected from the following methylation biomarkers:

[0035] chr1:1137001-1137301、chr1:145573620-145573920、chr1:155620501-155620801、chr1:184006347-184006405、chr1:205631898-205632198、chr1:230208001-230208301、chr1:29564367-29564667、chr1:58234801-58235101、chr1:87767701-87768001、chr1:91089001-91089301、chr1:147487202-147487501、chr1:147532802-147533101、chr1:181059009-181059309、chr1:181059309-181059609、chr1:94146733-94146927、chr10:133506601-133506901、chr10:2095501-2095801、chr10:482262-482562、chr10:77158920-77159220、chr10:91330501-91330801、chr10:17270986-17271286、chr10:73156539-73156552、chr10:79397203-79397502、chr11:2867401-2867701、chr11:45672001-45672301、chr11:64875601-64875901、chr11:836101-836401、chr11:86900101-86900401、chr11:17373393-17373693、chr12:125076301-125076601、chr12:125139301-125139601、chr12:133353801-133354101、chr12:87835801-87836101、chr12:104851940-104852240、chr12:49393272-49393353、chr14:90849279-90849579、chr14:91579987-91580287、chr15:102303001-102303301、chr15:39872388-39872688、chr15:102286047-102286347、chr15:45479869-45480127、<h2 style=";text-align:left;direction:ltr">chr15: 72667882-72668182、chr16: 1730317-1730617、chr16: 5337901-53 38201、chr16:83691601-83691901、chr17:80072101-80072401、chr17:316 19207-31619225, chr18: 150901-151201, chr18: 76273801-76274101, chr19: 16680412-16680712, chr19: 29613901-29614201, chr19: 38978952-389 79252, chr19: 38996401-38996701, chr19: 49703623-49703923, chr19: 49703923-49704223, chr19: 50944201-50944501, chr19: 51303278-51303578 、chr19: 39282525-39282825、chr2: 170552044-170552344、chr2: 1705523 44-170552375、chr2:177023775-177024075、chr2:20068960-20069094、ch r2:2275801-2276101、chr2:240033301-240033601、chr2:240033601-240 033901、chr2:47703601-47703901、chr2:88690201-88690501、chr2:99796 148-99796448, chr20: 29804820-29805120, chr20: 56247772-56248072, chr20: 4803590-4803717, chr21: 11169301-11169601, chr21: 27041008-270 41308, chr21: 45078301-45078601, chr21: 28219250-28219313, chr22: 39855601-39855901, chr22: 46969801-46970101, chr22: 51177001-51177301 chr22: 24199607-24199629, chr3: 145173301-145173601, chr3: 184243114-184243414, chr3: 193119901-193120201, chr3: 197113944-197114244<h2 style=";text-align:left;direction:ltr">chr3:79606801-79607101、chr3:93744201-93744501、chr3:98381701-9 8382001、chr3:50274237-50274536、chr4:1039501-1039801、chr4:15172 6801-151727101、chr4:44450164-44450464、chr4:9241061-9241361、chr 4:9245629-9245929、chr4:185937927-185937986、chr5:111409501-1114 09801, chr5: 149985301-149985601, chr5: 171576901-171577201, chr5: 175119901-175120201, chr5: 178398013-178398313, chr5: 178408306-178 408606、chr5:63373501-63373801、chr5:79331327-79331526、chr5:9495 6093-94956392、chr6:131404801-131405101、chr6:161273487-16127378 7、chr6: 105584593-105584757、chr6: 107810663-107810821、chr6: 1313 83975-131383979、chr6:26189401-26189431、chr7:144835801-14483610 1, chr7: 154592101-154592401, chr7: 155135101-155135401, chr7: 157485729-157486029, chr7: 20823318-20823618, chr7: 56230801-56231101, c hr7:56357341-56357641,chr7:7605460-7605760,chr7:7606060-7606112,chr7:7612688-7612988,chr7:7612988-7613288,chr7:7613288-76135 88, chr7: 134144180-134144289, chr7: 23513704-23514004, chr7: 23514004-23514120, chr8: 110882401-110882701, chr8: 126445404-126445704chr8:131455029-131455329、chr8:55002982-55003282、chr8:65711134-65711434、chr8:7830601-7830901、chr8:86566135-86566435、chr8:95182801-95183101、chr8:99954843-99955143、chr8:144853418-144853717、chr9:130529101-130529401、chr9:137378101-137378401、chr9:44868901-44869201、chr9:97317483-97317783、chr9:102585769-102586068、chr9:27529891-27530023、chr9:37036916-37037215、chr9:93955005-93955305、chrX:100672978-100673278、chrX:114468337-114468637、chrX:115005001-115005301、chrX:32723401-32723701、chrY:13489201-13489501。、

[0036] and another 35 methylation markers derived from Chinese patent application No. 202211120273.0 (chr1: 205532103-205532401, chr10: 2565003-2565301, chr11: 134253603-134253901, chr11: 46316648-46316946, chr11: 830025-830323, chr12: 113779503-113779801, chr12: 13117403-13117401, 703-124956001, chr12: 77272466-77272764, chr15: 96906603-96906901, chr15: 45406119-45406417, chr15: 33219303-33219601 , chr16: 74440716-74441014, chr17: 79652103-79652401, chr19: 55994103-55994401, chr19: 49636737-49637035, chr2: 16332360 3-163323901, chr2: 103445403-103445701, chr2: 111875389-111875687, chr20: 21493409-21493707, chr20: 21497940-21498238 , chr22: 50623397-50623695, chr22: 50988003-50988301, chr22: 42307184-42307431, chr4: 95579714-95580012, chr5: 148252503 -148252801, chr5: 170744972-170745270, chr5: 172070703-172071001, chr6: 26189103-26189401, chr7: 2376603-2376901, chr7 :5006703-5007001, chr7: 21765303-21765601, chr8: 10586552-10586850, chr8: 23583988-23584286, chr9: 26547903-26548201).

[0037] Wherein, the methylation marker is a test sample of a subject's blood, such as plasma, serum or blood. The detection reagent of the combination marker may include primers and / or probes for detecting the methylation level of each gene in the combination marker.

[0038] In some embodiments of the present invention, a method for methylation markers and combinations thereof is also involved, which involves extracting cfDNA from biological samples (including but not limited to tumor tissue, serum, plasma, and urine), then preparing libraries, and then performing high-throughput sequencing on the sequencing libraries using Illumina's HiSeqXten to detect 171 methylation markers at a time, and building a classification model through a machine learning algorithm to achieve accurate classification of prostate cancer patients with metastasis and non-metastasis, as well as patients with high-load metastasis and low-load metastasis.

[0039] Receiver operating characteristic curve (ROC line): It is a curve drawn based on a series of different binary classification methods (cutoff values ​​or decision thresholds), with sensitivity (true positive rate) as the vertical axis and 1-specificity (false positive rate) as the horizontal axis. The area under the ROC curve is an important indicator of test accuracy. The larger the area under the ROC curve, the greater the diagnostic value of the test.

[0040] In the embodiment of the present invention, for the detection method of detecting the differential methylation marker of cfDNA in metastatic prostate cancer, the specific detection steps are given as follows:

[0041] 1. Extraction of plasma cfDNA;

[0042] Specifically: When extracting plasma cfDNA, the specific operating steps are carried out according to the operating instructions of QIAamp Circulating Nucleic Acid Kit of QIAGEN.

[0043] 2. Bisulfite conversion;

[0044] Specifically, 20 ng of cfDNA was added for bisulfite conversion, so that the unmethylated cytosine in the DNA was deaminated and converted into uracil, while the methylated cytosine remained unchanged, to obtain bisulfite-converted DNA. The specific operation of the above conversion process was carried out according to the instructions of Zymo Research's EZ DNA Methylation-Gold Kit.

[0045] 3. Methylation library construction;

[0046] The specific steps include:

[0047] 3.1, Sex change;

[0048] 3.1.1. Place 15ul of the transformed sample in a PCR instrument and follow the following procedure:

[0049] 95℃ for 2min

[0050] Heating cover 105℃

[0051] 3.1.2. After the PCR reaction is completed, take out the sample immediately, put it directly into ice, and leave it for more than 2 minutes before proceeding to the next step.

[0052] 3.2, T7 connector connection;

[0053] 3.2.1. Prepare the reaction solution according to the following system;

[0054]

[0055]

[0056] 3.2.2. Place the sample in a PCR instrument and perform the reaction according to the following procedure:

[0057] 37℃ 15min

[0058] 95℃ 2min

[0059] 4℃

[0060] Heating cover 105℃

[0061] 3.3, Second strand synthesis;

[0062] 3.3.1. Prepare the reaction solution according to the following system

[0063] Components Volume(ul) Reagent Y1 2 Enzyme Y2 42 The product of the previous reaction 40 Total volume 84

[0064] 3.3.2. Place the sample in a PCR instrument and perform the reaction according to the following procedure:

[0065] 98℃ 1min

[0066] 62℃ 2min

[0067] 65℃ 5min

[0068] 4℃ hold

[0069] Heating cover 105℃

[0070] 3.4, first purification;

[0071] 3.4.1. After centrifuging the reaction product from the previous step, add 101ul of Agencourt AMPure Beads (which have been allowed to stand and equilibrate to room temperature in advance) to each sample and mix by pipetting;

[0072] 3.4.2. Let stand at room temperature for 5 minutes, transfer to a magnetic rack and let stand for 5 minutes, then discard the supernatant carefully;

[0073] 3.4.3 Keep the PCR tube on the magnetic rack, add 200ul 80% ethanol, let stand for 30s, and aspirate the ethanol;

[0074] 3.4.4. Repeat step 3.4.3 once;

[0075] 3.4.5. Open the lid and dry the magnetic beads for 2-3 minutes. After the alcohol is completely evaporated, place the PCR tube on the magnetic rack, add 15ul of Low EDTA TE, mix well by pipetting, and let stand at room temperature for 5 minutes.

[0076] 3.4.6. Place the PCR tube on the magnetic rack, let it stand at room temperature for 5 minutes, and then transfer 15ul of supernatant to a new PCR tube.

[0077] 3.5, T5 connector connection;

[0078] 3.5.1. Prepare the reaction solution according to the following system

[0079]

[0080]

[0081] 3.5.2. Place the sample in a PCR instrument and perform the reaction according to the following procedure:

[0082] 25℃ 15min

[0083] 4℃ hold

[0084] 3.6, second purification;

[0085] 3.6.1. After centrifuging the reaction products from the previous step, add 36ul of Agencourt AMPure Beads (which have been allowed to stand and equilibrate to room temperature in advance) to each sample and mix by pipetting;

[0086] 3.6.2. Let stand at room temperature for 5 minutes, transfer to a magnetic rack and let stand for 5 minutes, then carefully discard the supernatant;

[0087] 3.6.3. Keep the PCR tube on the magnetic rack, add 200ul 80% ethanol, let stand for 30s, and aspirate the ethanol;

[0088] 3.6.4. Repeat step 3.6.3 once;

[0089] 3.6.5. Open the lid and dry the magnetic beads for 2-3 minutes. After the alcohol is completely evaporated, place the PCR tube on the magnetic rack, add 20ul of Low EDTA TE, mix well by pipetting, and let stand at room temperature for 5 minutes.

[0090] 3.6.6. Place the PCR tube on the magnetic rack, let it stand at room temperature for 5 minutes, and then transfer 20ul of supernatant to a new PCR tube.

[0091] 3.7、Indexing PCR;

[0092] 3.7.1. Prepare the reaction solution according to the following system

[0093] Components Volume(ul) Low EDTA TE 10 Buffer R1 10 Reagent R2 4 Enzyme R3 1 PCR Index Primer 5 The product of the previous reaction 20 Total volume 50

[0094] 3.7.2. Place the sample in a PCR instrument and perform the reaction according to the following procedure:

[0095]

[0096] 3.8, third purification;

[0097] 3.8.1. After centrifuging the reaction products from the previous step, add 40ul of Agencourt AMPure Beads (which have been allowed to stand and equilibrate to room temperature in advance) to each sample and mix by pipetting;

[0098] 3.8.2. Let stand at room temperature for 5 minutes, transfer to a magnetic rack and let stand for 5 minutes, then carefully discard the supernatant;

[0099] 3.8.3. Keep the PCR tube on the magnetic rack, add 200ul 80% ethanol, let stand for 30s, and aspirate the ethanol;

[0100] 3.8.4. Repeat step 3.8.3 once;

[0101] 3.8.5. Open the lid and dry the magnetic beads for 2-3 minutes. After the alcohol has completely evaporated, place the PCR tube on the magnetic rack, add 20ul of Low EDTA TE, mix well by pipetting, and let stand at room temperature for 5 minutes.

[0102] 3.8.6. Place the PCR tube on the magnetic rack, let it stand at room temperature for 5 minutes, and then transfer 20ul of supernatant to a new PCR tube.

[0103] 4. Methylation rapid hybridization assay;

[0104] The specific steps include:

[0105] 4.1. Calculate the amount of different DNA libraries and mix them evenly in a centrifuge tube. The amount of each library should not exceed 500ng and the total amount should not exceed 4ug.

[0106] 4.2. Add the following pre-hybridization reagents to the mixed sample and mix well. The table is as follows

[0107] Components Volume(ul) Probe Panel 4 Universal sealer 8 Blocking agent solution 5

[0108] 4.3. Dry the mixed pre-hybridization reagents at room temperature in a vacuum concentrator;

[0109] 4.4. Add 20ul Fast Hybridization Mix to the dried sample and mix gently with your fingertips;

[0110] 4.5. Add 30ul Hybridization Enhancer to the surface of the above reagents;

[0111] 4.6. Place in PCR instrument and perform reaction according to the following procedure:

[0112] 95℃ 5min

[0113] 75℃ 2h

[0114] 60℃ 14h

[0115] Heating cover 85℃

[0116] 4.7. Equilibrate the streptavidin magnetic beads to room temperature in advance and transfer 100ul of magnetic beads to a 1.5ml centrifuge tube.

[0117] 4.8. Add 200ul of binding buffer and mix well by pipetting. Place the centrifuge tube on a magnetic rack for 1 minute or until the solution is clear, and discard the supernatant.

[0118] 4.9. Repeat step 4.8 twice, for a total of three washes.

[0119] 4.10. After the last wash, add 200ul of binding buffer, mix thoroughly, and transfer all the hybridization solution in the PCR instrument to the balanced magnetic beads.

[0120] 4.11. Mix the magnetic beads with hybridization solution thoroughly on a mixer at room temperature for 30 minutes.

[0121] 4.12. Remove the centrifuge tube from the mixer, centrifuge quickly, place it on the magnetic rack for 1 minute, and remove the supernatant.

[0122] 4.13. Add 200ul preheated washing solution 1, mix well, incubate at 65℃ for 5min, transfer to the magnetic rack and let stand for 1min, and carefully discard the supernatant.

[0123] 4.14. Repeat step 4.13 once.

[0124] 4.15. Add 200ul preheated Wash Solution 2, mix well, incubate at 48℃ for 5min, transfer to a magnetic rack and let stand for 1min, and carefully discard the supernatant.

[0125] 4.16. Repeat step 4.15 twice, for a total of three times.

[0126] 4.17. Add 45ul of water, mix well, and incubate the solution on ice.

[0127] 4.18. Prepare the reaction solution according to the following system

[0128]

[0129] 4.19. Place the sample in a PCR instrument and perform the reaction according to the following procedure:

[0130]

[0131]

[0132] 4.20. Add 90ul of DNA purification magnetic beads (allowed to equilibrate to room temperature in advance) to the amplified product and mix well.

[0133] 4.21. Let stand at room temperature for 5 min, transfer to a magnetic rack and let stand for 5 min, then carefully discard the supernatant.

[0134] 4.22. Keep the PCR tube on the magnetic rack, add 200ul 80% ethanol, let it stand for 30s, and then aspirate the ethanol.

[0135] 4.23. Repeat step 4.22 once.

[0136] 4.24. Open the lid and dry the magnetic beads for 2-3 minutes. After the alcohol is completely evaporated, place the PCR tube on the magnetic rack, add 32ul of water, mix well by pipetting, and let stand at room temperature for 5 minutes.

[0137] 4.25. Place the PCR tube on the magnetic rack, let it stand at room temperature for 5 minutes, and then transfer 30ul of supernatant to a new PCR tube.

[0138] 5. Use Illumina's sequencer to sequence the samples after hybridization capture to obtain sequencing results.

[0139] 6. Perform routine bioinformatics analysis on the raw data from the sequencer to obtain the methylation data of the target region, the methylation differential region signal and the specific methylation fragment, and use the constructed algorithm model (see Appendix) to Figure 1 ), calculate the metastatic prostate cancer score and the prostate cancer metastasis burden score. The algorithm calculation process is as follows:

[0140] 6.1. According to the targeted methylation region designed in this patent, the methylation ratio value of the region and the methylation fragment information of the region are obtained respectively. After the methylation ratio level is calculated by the Bismark software for the CpG site, all CpG methylation sites of all fragments in the region are weighted averaged according to the modified regional methylation site calculation method. The methylation fragment information is constructed by summarizing the base information of all fragments of the sequence ATCG and methylated C after removing the low-quality region (sequencing read length 5' end 25bp) from all sequencing fragments of the targeted methylation region.

[0141] 6.2. For the methylation fragment information of the region, the tissue LSTM model and Transformer model trained based on the constructed metastatic prostate cancer methylation fragment database are used to one-hot encode the methylation fragments, and then the tissue methylation score of the sample is calculated using the tissue model.

[0142] 6.3. For the methylation ratio value of the region, the blood methylation score of the sample was calculated based on the established metastatic prostate cancer blood methylation database and established models, including the random forest model (RF), XGBoost model and generalized linear model (GLM).

[0143] 6.4. Based on the tissue methylation score and blood methylation score of the sample, the prostate cancer tumor metastasis score and metastasis burden score of the sample are calculated using the generalized linear model trained with the metastatic prostate cancer label and the metastatic tumor burden label.

[0144] The present application is further described below through specific embodiments, but is not intended to limit the scope of protection of the present invention.

[0145] Example 1

[0146] This example first uses the whole genome and various combinations of methylation sequencing data of 188 pairs of prostate cancer tissue / para-cancer paired in the CPGEA database to construct a prostate cancer tissue methylation fragment information database; uses the whole genome and various combinations of methylation sequencing data of cfDNA in blood of 534 prostate cancer patients and the whole genome and various combinations of methylation data of cfDNA in blood of 208 male puncture-negative patients of the same age group to construct a blood methylation database. Secondly, based on data analysis and difference screening, 18,799 targeted methylation sites in the region were constructed. Then this example uses 18,799 sites for 25 tumor tissues, 18 non-tumor tissues and 108 healthy people's blood data, using Figure 1The modeling method was used to construct a methylation tissue model for prostate cancer; the methylation sequencing data of 534 prostate cancer blood cfDNA whole genome and various combinations thereof and the methylation data of 208 male puncture-negative patients in the same age group were used. Figure 1 The modeling method is used to construct a blood methylation model for prostate cancer. This embodiment combines the prostate cancer tissue methylation model and the blood methylation model through an integrated model method, and finally screens out 171 methylation site combinations as the input sites of the model and the detection sites of prostate cancer in the design of this patent, and finally gives the prostate cancer metastasis ratio score and metastasis load score in combination with clinical information. The final model metastasis signal score below 0.03% is non-metastasis, the signal value between 0.03% and 0.3% is low-load metastasis, and the signal value above 0.3% is high-load metastasis.

[0147] Example 2

[0148] In this example, plasma cfDNA was extracted from 70 patients with localized prostate cancer and 43 patients with metastatic prostate cancer, and then bisulfite conversion was performed. The methylation levels of the whole genome and various combinations of the samples were measured using the experimental steps and bioinformatics analysis methods consistent with the methylation library construction, methylation rapid hybridization, and sample sequencing methods described in this application. Then, we extracted the methylation level measurement values ​​of the combination of the 171 methylation markers mentioned in this application; then, 60% were randomly selected as training set samples, and a classification model was constructed using random forests, and the remaining 40% were used as a test set; we predicted the metastasis status of prostate cancer for the samples;

[0149] See attached for the results Figure 2 As shown in Figure 2, at a specificity of 96.1%, the overall sensitivity for detecting metastatic prostate cancer and non-metastatic prostate cancer was 95.2%, and the overall AUC was 0.987. The scatter plot of the significant separation of the discrimination scores between the metastatic prostate cancer patient group and the non-metastatic prostate cancer patient group (refer to Figure 3 ). The above results indicate that the methylation markers of the present invention combined with the machine learning algorithm of the present invention can accurately distinguish patients with metastatic prostate cancer from patients with non-metastatic prostate cancer.

[0150] Example 3

[0151] In this example, plasma cfDNA was extracted from 20 patients with low tumor load of metastatic prostate cancer and 23 patients with high tumor load of metastatic prostate cancer, and then bisulfite conversion was performed. The methylation levels of the whole genome and various combinations of the samples were measured using the experimental steps and bioinformatics analysis methods consistent with the methylation library construction, methylation rapid hybridization, and sample sequencing methods described in this application. Then, we extracted the methylation level measurement values ​​of the combination of the 171 methylation markers mentioned in this application; then, 60% were randomly selected as training set samples, and a classification model was constructed using logistic regression, and the remaining 40% were used as a test set; then, we predicted the degree of prostate cancer tumor load for these samples.

[0152] Differentiation of tumor burden in metastatic prostate cancer Figure 4 As shown, at 90% specificity, the overall sensitivity of detecting high tumor load and low tumor load is 91.3%, and the overall AUC is 0.972. The above results show that the methylation markers of the present invention combined with the machine learning algorithm of the present invention can accurately distinguish between patients with high metastatic load prostate cancer and patients with low metastatic load prostate cancer.

[0153] The above only describes some exemplary embodiments of the present invention by way of illustration. It is undoubted that, for those skilled in the art, without departing from the spirit and scope of the present invention, the described embodiments can be improved and supplemented in various ways, and these improvements and supplements should also be regarded as the protection scope of the present invention. Therefore, the above drawings and descriptions are illustrative in nature and should not be construed as limiting the protection scope of the claims of the present invention.

Claims

1. A methylation biomarker combination for detecting tumor burden in metastatic prostate cancer, characterized in that: A global panel of sites selected from the following methylation biomarkers: chr 1: 1137001-1137301, chr 1: 145573620-145573920, chr 1: 155620501-155620801, chr 1: 184006347-184006405, chr 1: 205631898-205632198, chr 1: 230208001-230208301, chr 1: 29564367-29564667, chr 1: 58234801-58235101, chr 1: 87767701-87768001, chr 1: 91089001-91089301, chr 1: 147487202-147487501, chr 1: 147532802-147533101, chr 1: 181059009-181059309, chr 1: 181059309-181059609, chr 1: 94146733-94146927, chr 10: 133506601-133506901, chr 10: 2095501-2095801, chr 10: 482262-482562, chr 10: 77158920-77159220, chr 10: 91330501-91330801, chr 10: 17270986-17271286, chr 10: 73156539-73156552, chr 10: 79397203-79397502, chr 11: 2867401-2867701, chr 11: 45672001-45672301, chr 11:64875601-64875901、chr 11:836101-836401、chr 11:86900101-86900401、chr 11:17373393-17373693、chr 12:125076301-125076601、chr 12:125139301-125139601、chr 12:133353801-133354101、chr12:87835801-87836101、c hr 12:104851940-104852240、c hr 12:49393272-49393353、chr 14:90849279-90849579、c hr 14:91579987-91580287、c hr 15:102303001-102303301、c hr 15:39872388-39872688、c hr15:102286047-102286347、c hr 15:45479869-45480127、c hr 15:72667882-72668182、c hr 16:1730317-1730617、c hr 16:5337901-5338201、c hr 16:83691601-83691901、c hr 17:80072101-80072401、c hr 17:31619207-31619225、c hr 18:150901-151201、c hr 18:76273801-76274101、c hr 19:16680412-16680712、c hr 19:29613901-29614201、c hr 19:38978952-38979252、c hr19:38996401-38996701、c hr 19:49703623-49703923、c hr 19:49703923-49704223、c hr19:50944201-50944501、c hr 19:51303278-51303578、c hr 19:39282525-39282825、c hr2:170552044-170552344、c hr 2:170552344-170552375、c hr 2:177023775-177024075、chr 2:20068960-20069094、c hr 2:2275801-2276101、c hr 2:240033301-240033601、c hr2:240033601-240033901、c hr 2:47703601-47703901、c hr 2:88690201-88690501、c hr2:99796148-99796448、c hr 20:29804820-29805120、c hr 20:56247772-56248072、chr20:4803590-4803717、chr21:11169301-11169601、chr21:27041008-27041308、chr21:45078301-45078601、chr21:28219250-28219313、chr22:39855601-39855901、chr22:46969801-46970101、chr22:51177001-51177301、chr22:24199607-24199629、chr3:145173301-145173601、chr3:184243114-184243414、chr3:193119901-193120201、chr3:197113944-197114244、chr3:79606801-79607101、chr3:93744201-93744501、chr3:98381701-98382001、chr3:50274237-50274536、chr4:1039501-1039801、chr4:151726801-151727101、chr4:44450164-44450464、chr4:9241061-9241361、chr4:9245629-9245929、chr4:185937927-185937986、chr5:111409501-111409801、chr5:149985301-149985601、chr5:171576901-171577201、chr5:175119901-175120201、chr5:178398013-178398313、chr5:178408306-178408606、chr5:63373501-63373801、chr5:79331327-79331526、chr5:94956093-94956392、chr6:131404801-131405101、chr6:161273487-161273787、chr6:105584593-105584757、chr6:107810663-107810821、chr6:131383975-131383979、chr6:26189401-26189431、chr7:144835801-144836101、chr 7:154592101-154592401、chr 7:155135101-155135401、chr7:157485729-157486029、chr 7:20823318-20823618、c hr 7:56230801-56231101、chr 7:56357341-56357641、c hr 7:7605460-7605760、c hr 7:7606060-7606112、chr 7:7612688-7612988、chr 7:7612988-7613288、chr 7:7613288-7613588、chr 7:134144180-134144289、chr 7:23513704-23514004、chr 7:23514004-23514120、chr8:110882401-110882701、chr8:126445404-126445704、chr 8:131455029-131455329、chr8:55002982-55003282、chr8:65711134-65711434、chr8:7830601-7830901、chr 8:86566135-86566435、c hr8:95182801-95183101、chr8:99954843-99955143、chr8:144853418-144853717、chr 9:130529101-130529401、chr9:137378101-137378401、chr9:44868901-44869201、chr9:97317483-97317783、chr9:102585769-102586068、chr9:27529891-27530023、chr9:37036916-37037215、chr9:93955005-93955305、chrX:100672978-100673278、chrX:114468337-114468637、chrX:115005001-115005301、chrX:32723401-32723701、chrY:13489201-13489501; and another 35 methylation markers derived from Chinese patent application No. 202211120273.

0.

2. The methylation biomarker combination for detecting tumor burden in metastatic prostate cancer according to claim 1, characterized in that: The methylation biomarker combination is used to prepare a detection kit.

3. The methylation biomarker combination for detecting tumor burden in metastatic prostate cancer according to claim 2, characterized in that: The detection kit is used for detecting prostate cancer tumor load.

4. The methylation biomarker combination for detecting tumor burden in metastatic prostate cancer according to any one of claims 1 to 3, characterized in that: The detection method of the methylation biomarker combination comprises the following steps: Step 1: Extract cfDNA from the blood sample to be tested; Step 2: Treat the extracted cfDNA with bisulfite to obtain a converted cfDNA sample; Step 3: Construct a methylated DNA library for the converted cfDNA samples; Step 4: Construction of targeted hybrid capture methylation and library for prostate cancer; Step 5: high-throughput sequencing to obtain probe-captured data; Step 6: Methylation data analysis, confirming the final metastatic prostate cancer signal and metastatic tumor burden signal based on the methylation markers and algorithm model.

5. The methylation biomarker combination for detecting tumor burden in metastatic prostate cancer according to claim 4, characterized in that: When analyzing the methylation data in step 6, conventional bioinformatics analysis is performed on the raw data from the sequencer.

6. The methylation biomarker combination for detecting tumor burden in metastatic prostate cancer according to claim 4, characterized in that: The blood sample to be tested in step 1 is plasma, serum or blood.

7. The methylation biomarker combination for detecting tumor burden in metastatic prostate cancer according to claim 4, characterized in that: In step 5, high-throughput sequencing is performed using the sequencing library, and the sequencing can be performed by any sequencing method, including second-generation sequencing technology or single-molecule sequencing technology.

Citation Information

Patent Citations

  • Methylated biomarker combination for detecting metastatic prostate cancer and application

    CN115466791A

  • Methylated biomarker combination for detecting metastatic prostate cancer tumor load and application

    CN117487920A